Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdvanTIG-202: Ociperlimab + Tislelizumab in Recurrent/Metastatic Cervical Cancer
NCT04693234Phase 2Completed
- Sponsor
- BeiGene
- Start
- Feb 2021
- Primary completion
- Jun 2022
- Modality
- IgG Antibodies, Immune Checkpoint Inhibitors
- Countries
- 8
01
Overview
A Phase 2 trial of ociperlimab in Cervical Cancer (CC), sponsored by BeiGene. Started Feb 2021; status: completed.
02
Drugs
ociperlimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04693234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04693234.